Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape

Cameron J Turtle; David G Maloney

doi:10.1080/17474086.2016.1203251

Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape

Expert Rev Hematol. 2016 Aug;9(8):719-21. doi: 10.1080/17474086.2016.1203251. Epub 2016 Jul 4.

Authors

Cameron J Turtle^{1

2}, David G Maloney^{1

2}

Affiliations

¹ a Clinical Research Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
² b Department of Medicine , University of Washington , Seattle , WA , USA.

PMID: 27322438
DOI: 10.1080/17474086.2016.1203251

No abstract available

Keywords: Chimeric antigen receptor; T cells; acute lymphoblastic leukemia; cellular therapy; chronic lymphocytic leukemia; immunotherapy; non-Hodgkin lymphoma.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19
Cell- and Tissue-Based Therapy*
Clinical Trials as Topic
Humans
Immunotherapy, Adoptive
Receptors, Antigen, T-Cell
Recoverin

Substances

Antigens, CD19
RCVRN protein, human
Receptors, Antigen, T-Cell
Recoverin